Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology...
Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. These awards across several geographies recognize the progress represented by Voranigo® for patients...